Personalized radiation pulses could boost esophageal cancer treatment

NCT ID NCT07700420

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial tests whether adding a personalized, ultra-precise radiation technique called PULSAR to standard chemotherapy and immunotherapy is safe for people with esophageal or gastro-esophageal junction cancer. The study aims to find the best radiation dose that can be given without causing severe side effects. Participants will receive the usual chemo and immunotherapy plus the new radiation schedule before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of chemotherapy (FLOT: fluorouracil, leucovorin, oxaliplatin, docetaxel), immunotherapy (durvalumab), and personalized radiation (PULSAR)
What this could lead to
If successful, this approach could lead to a more effective treatment for esophageal cancer that combines radiation, chemo, and immunotherapy to improve outcomes.
What could go wrong
This is an early phase I trial with only 15 participants, so the main goal is safety, not effectiveness. The radiation dose may cause side effects, and the combination may not work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.